fingolimod (Gilenya)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Sclerosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Relapse prevention and slowing physical disability progression in adults with multiple sclerosis (Gilenya, Novartis Pharma K.K.; Imusera, Mitsubishi Tanabe Pharma)
Product first approved 2011pj.jiho.jp
EU
  • Single disease modifying therapy in highly active relapsing remitting multiple sclerosis
Product first approved 2011EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (22)
Multiple Sclerosis
NCT01892722 · Novartis Pharmaceuticals
2013-07-26 – 2030-02-18 · Multiple Sclerosis
What this study did
NCT01201356 · Novartis Pharmaceuticals
2010-09-13 – 2018-10-19 · Relapsing Forms of Multiple Sclerosis
What this study did
NCT01633112 · Novartis Pharmaceuticals
2012-08-09 – 2018-04-30 · Relapsing-remitting Multiple Sclerosis (RRMS)
What this study did
NCT01941004 · Novartis Pharmaceuticals
2014-06 – 2017-05 · Multiple Sclerosis (Relapsing Remitting)
What this study did
NCT00731692 · Novartis Pharmaceuticals
2008-07-28 – 2015-06-22 · Primary Progressive Multiple Sclerosis
What this study did
NCT01497262 · Novartis Pharmaceuticals
2012-02 – 2014-04 · Multiple Sclerosis
What this study did
NCT01499667 · Novartis Pharmaceuticals
2011-09 – 2012-11 · Relapsing Remitting Multiple Sclerosis (RRMS)
What this study did
NCT01127750 · Novartis
2010-05 – 2011-10 · Relapsing Multiple Sclerosis
What this study did
NCT00355134 · Novartis
2006-06 – 2011-08 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT01625182 · Novartis Pharmaceuticals
2012-12-22 – 2016-09-03 · Chronic Inflammatory Demyelinating Polyradiculoneuropathy
What this study did
NCT00239811 · Novartis Pharmaceuticals
2004-04 – 2006-05 · Renal Transplantation
What this study did
NCT00239863 · Novartis Pharmaceuticals
2004-05 – 2006-05 · Renal Transplantation
What this study did
NCT00098735 · Novartis Pharmaceuticals
2004-04 – 2006-04 · Kidney Transplantation
What this study did
NCT00099801 · Novartis Pharmaceuticals
2005-01 – 2006-03 · Kidney Transplantation
What this study did
NCT00239876 · Novartis Pharmaceuticals
2005-05 – 2005-12 · Renal Transplantation
What this study did
NCT00099736 · Novartis Pharmaceuticals
2003-05-07 – 2005-09-19 · Kidney Transplantation
What this study did
NCT00239785 · Novartis Pharmaceuticals
2003-04 – 2005-04 · Renal Transplantation
What this study did
Phase 2/3 (3)
Multiple Sclerosis
NCT07220252 · TG Therapeutics, Inc.
2026-07-01 – 2033-06-30 · Relapsing Multiple Sclerosis
What this study did
NCT02939079 · Isfahan University of Medical Sciences
2015-04 – 2016-10 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT00099749 · Novartis Pharmaceuticals
2003-11 – 2006-04 · Kidney Transplantation
What this study did
Phase 2 (17)
Multiple Sclerosis
NCT00670449 · Novartis
2008-04 – 2012-04 · Multiple Sclerosis
What this study did
NCT00333138 · Novartis
2003-05 – 2011-04 · Multiple Sclerosis
What this study did
NCT00537082 · Novartis
2007-09 – 2010-02 · Multiple Sclerosis
What this study did
Other / comorbidity
NCT06424067 · Medical University of South Carolina
2025-05-01 – 2028-05-01 · Non Small Cell Lung Cancer, Small-cell Lung Cancer
What this study did
NCT05285878 · The Methodist Hospital Research Institute
2022-07-28 – 2027-12 · Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
What this study did
NCT04675762 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-01-15 – 2026-03-15 · Stroke, Inflammation
What this study did
NCT04629872 · Ning Wang, MD., PhD.
2020-11-12 – 2023-12-30 · Stroke Inflammation
What this study did
NCT04280588 · First Affiliated Hospital of Fujian Medical University
2020-02-22 – 2020-07-01 · Coronavirus Disease (COVID-19)
What this study did
NCT02956200 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2016-11 – 2018-12 · Stroke, Inflammation
What this study did
NCT01779700 · Indiana University
2013-01 – 2016-08 · Schizophrenia
What this study did
NCT01786174 · Massachusetts General Hospital
2013-08 – 2015-05 · Amyotrophic Lateral Sclerosis
What this study did
NCT02002390 · Tianjin Medical University General Hospital
2012-10 – 2014-10-01 · Stroke, Vascular Accident, Cerebral Stroke, Ischemic Cerebrovascular Accident, Stroke, Acute
What this study did
NCT01791192 · Novartis Pharmaceuticals
2013-11 – 2014-10 · Acute Noninfectious Posterior, Intermediate, or Pan Uveitis
What this study did
NCT01757691 · Novartis Pharmaceuticals
2013-08 – 2014-05 · Acute Demylelinating Optic Neuritis
What this study did
NCT00785083 · Novartis
2008-09 – 2009-02 · Asthma
What this study did
NCT00239798 · Novartis Pharmaceuticals
2004-11 – 2006-11 · Renal Transplantation
What this study did
NCT00239902 · Novartis Pharmaceuticals
2002-05 – 2004-11 · Renal Transplantation
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT06087965 · Tang-Du Hospital
2023-10-11 – 2025-12-30 · Intracerebral Hemorrhage
What this study did
NCT02061137 · University Hospital, Basel, Switzerland
2013-08 – 2018-04 · Rett's Syndrome
What this study did
Phase 1 (9)
Other / comorbidity
NCT04088630 · Wake Forest University Health Sciences
2020-08-07 – 2024-06-05 · Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
What this study did
NCT03941743 · Mayo Clinic
2019-12-12 – 2021-11-23 · Breast Carcinoma
What this study did
NCT03943498 · Mayo Clinic
2019-05-24 – 2020-12-10 · Chemotherapy-Induced Peripheral Neuropathy, Numbness, Pain, Tingling
What this study did
NCT02490930 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2015-07 – 2017-09 · Glioblastoma, Anaplastic Astrocytoma
What this study did
NCT03757338 · Asofarma S.A.I. y C.
2015-10-23 – 2016-01-26 · Healthy Volunteers
What this study did
NCT05145621 · Alembic Pharmaceuticals Ltd.
2015-10-29 – 2016-01-15 · Bioequivalence, Safety
What this study did
NCT00731523 · Novartis
2008-07 – 2008-08 · Renal Insufficiency
What this study did
NCT00416845 · Novartis
2006-10 – 2007-03 · Healthy
What this study did
Phase 4 (28)
Multiple Sclerosis
NCT04480853 · Novartis Pharmaceuticals
2020-10-12 – 2026-11-15 · Multiple Sclerosis
What this study did
NCT04667949 · Novartis Pharmaceuticals
2021-02-20 – 2025-03-25 · Relapsing Multiple Sclerosis (RMS)
What this study did
NCT02232061 · Novartis Pharmaceuticals
2014-09-29 – 2020-01-24 · Multiple Sclerosis
What this study did
NCT03345940 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
2017-04-30 – 2019-10-30 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT03257358 · Novartis Pharmaceuticals
2017-09-19 – 2019-06-28 · Relapsing Multiple Sclerosis
What this study did
NCT01705236 · Novartis Pharmaceuticals
2012-08-20 – 2019-02-18 · Relapsing Remitting Multiple Sclerosis RRMS
What this study did
NCT02373098 · Novartis Pharmaceuticals
2015-03-31 – 2017-01-18 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT01585298 · Novartis Pharmaceuticals
2012-04-29 – 2016-12-12 · Multiple Sclerosis
What this study did
NCT02720107 · Novartis Pharmaceuticals
2016-05-12 – 2016-11-14 · Relapsing-remitting Multiple Sclerosis
What this study did
NCT02325440 · University Hospital Muenster
2014-03 – 2016-04 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT01755871 · Heinrich-Heine University, Duesseldorf
2013-01 – 2016-02 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT01498887 · Novartis Pharmaceuticals
2011-12-24 – 2015-12-26 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT02307838 · Novartis Pharmaceuticals
2014-06 – 2015-12 · Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
What this study did
NCT01333501 · Novartis Pharmaceuticals
2011-05 – 2015-09 · Multiple Sclerosis
What this study did
NCT01623596 · Novartis Pharmaceuticals
2012-06-08 – 2015-07-13 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT02048072 · Jochen Vehoff
2013-07 – 2015-06 · Multiple Sclerosis, Autonomic Nervous System Dysfunction
What this study did
NCT01578330 · Novartis Pharmaceuticals
2012-10 – 2015-04 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT01490840 · Novartis Pharmaceuticals
2011-11 – 2014-07 · Fatigue in Multiple Sclerosis
What this study did
NCT01621269 · Novartis Pharmaceuticals
2013-06 – 2014-06 · Multiple Sclerosis
What this study did
NCT01317004 · Novartis Pharmaceuticals
2011-05 – 2014-06 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT01436643 · Novartis Pharmaceuticals
2011-11 – 2013-09 · Depression, Relapsing-remitting Multiple Sclerosis
What this study did
NCT01709812 · Novartis Pharmaceuticals
2013-07 – 2013-07 · Relapsing-remitting Multiple Sclerosis
What this study did
NCT01534182 · Novartis Pharmaceuticals
2012-01 – 2013-06 · Relapsing Remitting Multiple Sclerosis
What this study did
NCT01420055 · Novartis Pharmaceuticals
2011-08 – 2013-06 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT01216072 · Novartis Pharmaceuticals
2010-08 – 2012-08 · Relapsing Forms of Multiple Sclerosis
What this study did
NCT01310166 · Novartis Pharmaceuticals
2011-02 – 2012-07 · Relapsing-remitting Multiple Sclerosis
What this study did
Other / comorbidity
NCT05307731 · General Hospital of Shenyang Military Region
2022-03-15 – 2028-03-15 · Diabetes Mellitus, Type 2
What this study did
NCT02575365 · Novartis Pharmaceuticals
2016-02-16 – 2017-01-27 · Cognition, Brain Volume Loss
What this study did
Early phase / not applicable (4)
Multiple Sclerosis
NCT03500328 · Johns Hopkins University
2018-05-02 – 2026-08-31 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT03243721 · The Cleveland Clinic
2017-10-20 – 2019-11-12 · Multiple Sclerosis
What this study did
NCT05684016 · George Washington University
2013-12 – 2016-12 · Multiple Sclerosis, Relapsing-Remitting
What this study did
Other / comorbidity
NCT04718064 · The Affiliated Hospital of Xuzhou Medical University
2021-02-01 – 2022-01-31 · Stroke
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Multiple Sclerosis
NCT06408259 · Bristol-Myers Squibb
2025-04-08 – 2036-07-13 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT04926818 · Novartis Pharmaceuticals
2021-10-05 – 2031-02-28 · Multiple Sclerosis (MS)
What this study did
NCT05123703 · Hoffmann-La Roche
2022-05-19 – 2029-09-17 · Relapsing-remitting Multiple Sclerosis
What this study did
Phase 1 (1)
Multiple Sclerosis
NCT02193217 · Tanabe Pharma Corporation
est. completion 2015-01 · Relapsing-remitting Multiple Sclerosis
What this study did
Phase 4 (1)
Multiple Sclerosis
NCT02342704 · Biogen
2014-11-30 – 2016-05-18 · Relapsing-Remitting Multiple Sclerosis
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Multiple Sclerosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fingolimod (Gilenya): this drugApprovedSmall moleculeS1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5), Sphingosine 1-phosphate receptor (S1PR, specifically S1P1)Reliable signal
NCT00289978: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47)
NCT00340834: Annualized relapse rate over 12 months: fingolimod 1.25 mg 0.20 (95% CI 0.16 to 0.26) and 0.5 mg 0.16 (95% CI 0.12 to 0.21) vs interferon beta-1a IM 0.33 (95% CI 0.26 to 0.42); p<0.001 for both comparisons. n=1,292 randomized (TRANSFORMS, Cohen 2010, NEJM).
AlemtuzumabApprovedMonoclonal antibodyCD52Partial signal
NCT00930553: Annualized Relapse Rate (ARR) (Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)): Alemtuzumab Treatment CAMMS323 Extension — Year 3: 0.19 relapses per participant per year; Year 4: 0.16 relapses per participant per year; Year 5: 0.15 relapses per participant per year; Year 6: 0.12 relapses per participant per year | Alemtuzumab Treatment CAMMS324 Extension — Year 3: 0.22 relapses per participant per year; Year 4: 0.24 relapses per participant per year; Year 5: 0.19 relapses per participant per year; Year 6: 0.16 relapses per participant per year
NCT00548405: Percentage of Participants With Sustained Accumulation of Disability (SAD) (Up to 2 years): Alemtuzumab 12 mg 12.71% (95% CI 9.89 to 16.27) vs Interferon Beta-1a 21.13% (95% CI 15.95 to 27.68)
BafiertamApprovedSmall moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
Cladribine (MAVENCLAD®)ApprovedSmall moleculeAdenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytesReliable signal
NCT00213135: Annualized Qualifying Relapse Rate (Week 96): Cladribine 5.25 mg/kg 0.15 relapses per year (95% CI 0.12 to 0.17) | Cladribine 3.5 mg/kg 0.14 relapses per year (95% CI 0.12 to 0.17) vs Placebo 0.33 relapses per year (95% CI 0.29 to 0.38)
CopaxoneApprovedPeptideMyelin basic protein-mimetic immunomodulationnot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Tecfidera)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Reliable signal
NCT00451451: Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo.
NCT00420212: Estimated proportion relapsed by 2 years: 27% with BG-12 240 mg twice daily and 26% with 240 mg three times daily vs 46% with placebo (P<0.001 for both comparisons) (DEFINE, N Engl J Med 2012).
Diroximel Fumarate (Vumerity)ApprovedSmall moleculeNrf2 pathway (fumaric acid ester)Weak signal
NCT03093324: Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003.
Etrasimod (Velsipity)
Approved(overall)
Small moleculeS1P receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Fampridine (Ampyra / Fampyra)ApprovedSmall moleculePotassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family)Partial signal
NCT00127530: Timed walk responders: fampridine 78/224 (35%) vs placebo 6/72 (8%), p<0.0001 (Goodman et al., Lancet 2009)
Interferon Beta-1a (Avonex)ApprovedBiologic (subtype unspecified)Type I Interferon receptor (IFNAR)Weak signal
NCT00211887: ARR - PDEs (Baseline to Month 36): IFN + GA 0.12 relapses per year | IFB-1a 0.16 relapses per year vs Glatiramer 0.11 relapses per year
Interferon Beta-1bApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorPartial signal
NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS
NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed
Natalizumab (Tysabri)ApprovedMonoclonal antibodyα4 integrinReliable signal
NCT00027300: Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001).
NCT03689972: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63)
OcrelizumabApprovedMonoclonal antibodyCD20Partial signal
NCT05123703: Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk.
NCT01247324: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2)
Ocrevus ZunovoApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
OfatumumabApprovedMonoclonal antibodyCD20Reliable signal
NCT02792231: Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09)
NCT02792218: Annualized relapse rate (median 1.6-year follow-up): 0.11 ofatumumab vs 0.22 teriflunomide; difference -0.11 (95% CI -0.16 to -0.06).
Ozanimod (Zeposia)ApprovedSmall moleculeS1P receptorPartial signal
NCT02047734: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose
NCT02294058: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period (12 months): Ozanimod 0.5 mg 0.241 relapses/year (95% CI 0.188 to 0.308) | Ozanimod 1 mg 0.181 relapses/year (95% CI 0.14 to 0.236) vs Interferon Beta-1a 0.35 relapses/year (95% CI 0.279 to 0.44)
Peginterferon Beta-1a (Plegridy)ApprovedBiologic (subtype unspecified)Type I interferon receptor, Interferon beta receptor (type I IFN signaling)Reliable signal
NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481)
NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037).
PonesimodApprovedSmall moleculeS1P receptorReliable signal
NCT02425644: Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001.
Rebif (interferon Beta 1a)ApprovedBiologic (subtype unspecified)Interferon beta receptor (type I IFN signaling), Type I interferon receptorWeak signalFeatured results are non-efficacy only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)Weak signalFeatured results are non-efficacy only in this race
Siponimod (Mayzent)ApprovedSmall moleculeS1P receptorWeak signal
NCT01665144: EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results).
Tascenso ODTApprovedSmall moleculeS1P receptornot yet gradedNo reviewed efficacy summary in this indication
Teriflunomide HMR1726 (Aubagio)ApprovedSmall moleculeDihydroorotate dehydrogenase (DHODH)Reliable signal
NCT03122652: Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction)
NCT00751881: Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results).
Tyruko (natalizumab-Sztn)ApprovedMonoclonal antibodyα4 integrinnot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)ApprovedMonoclonal antibodyCD20Reliable signal
NCT03277248: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291)
NCT03277261: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.076 relapses per participant-years (95% CI 0.042 to 0.138) | Teriflunomide + IV Placebo 0.188 relapses per participant-years (95% CI 0.124 to 0.283)
ABP 692Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
BCD-281Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
CT-P53Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 3Monoclonal antibodyCD20Reliable signal
NCT05385744: Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164
FenebrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
FrexalimabPhase 3Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
Mocravimod
Phase 3(overall)
Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
not yet graded(overall)
No reviewed efficacy summary in this indication
Nabiximols (Sativex)Phase 3BotanicalCannabinoid CB1/CB2 receptors (agonist)Partial signal
NCT04657666: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) (Baseline (predose Day 1 of Treatment Period 1) up to Day 51 (end of treatment of Treatment Period 2)): Nabiximols -0.23 units on a scale (Standard Error 0.07) vs Placebo -0.26 units on a scale (Standard Error 0.07) missed
NCT01610700: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks): GW-1000-02 -25.32 units on a scale (Standard Deviation 23.42) vs Placebo -19.32 units on a scale (Standard Deviation 27.02) missed
RemibrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
TolebrutinibPhase 3Small moleculeBruton's tyrosine kinase (BTK)Reliable signal
NCT04411641: HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results).
NCT04458051: 6-month composite confirmed disability progression (cCDP), tolebrutinib vs placebo: HR 1.01 (95% CI 0.81-1.26), p=.94 — no difference from placebo. missed
Vidofludimus CalciumPhase 3—Dihydroorotate dehydrogenase (DHODH)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismPartial signal
NCT04626921: LCLA (Best-Corrected Low-Contrast Letter Acuity) change across both eyes at Week 144 vs original randomization baseline, CNM-Au8 arm: least-squares mean difference +8.70 letters (SE 1.88), 95% CI 5.0 to 12.4, p<0.0001
Amiselimod
Phase 2(overall)
Small moleculeS1P receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
CorubrutinibPhase 2Small moleculeBruton's tyrosine kinase (BTK)Partial signal
NCT05798520: Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released)
ForalumabPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
IrafamdastatPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Tamuzimod
Phase 2(overall)
Small moleculeS1P receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
A-005
Phase 1(overall)
Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
IDP-023Phase 1Cell therapyAllogeneic g-NK cell therapynot yet gradedNo reviewed efficacy summary in this indication
RG6035
—(overall)
Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
RG6182
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BaminerceptDiscontinuedProtein / enzyme therapeuticLymphotoxin-beta receptor (LTβR)not yet gradedNo reviewed efficacy summary in this indication
Firategrast (SB-683699)DiscontinuedSmall moleculeVLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow fingolimod (Gilenya) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
May 2027 (1)
Phase 2Non Small Cell Lung Cancer, Small-cell Lung CancerRecruiting
Est. primary completion 2027-05-01 · NCT06424067 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection …Enrolling by invitation
Est. primary completion 2027-06 · NCT05285878 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 4Diabetes Mellitus, Type 2Recruiting
Est. primary completion 2028-03-15 · NCT05307731 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 2/3Multiple SclerosisRecruiting
Est. primary completion 2030-01-01 · NCT07220252 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 3Multiple SclerosisNot yet recruiting
Est. primary completion 2034-07-28 · NCT07483632 · CT.gov ↗
What to watch

See the full readout calendar ↗